胰高血糖素样肽-1受体激动剂在2型糖尿病心血管并发症中的研究进展  

Progress in the Study of GLP-1 Receptor Agonists in Cardiovascular Complications of Type 2 Diabetes Mellitus

作　　者：耿婧 GENG Jing(Health Service Center,Xiaobailou Street,Heping District,Tianjin 300040 China)

机构地区：[1]天津市和平区小白楼街社区卫生服务中心,天津300040

出　　处：《现代诊断与治疗》2020年第19期3041-3042,3190,共3页Modern Diagnosis and Treatment

摘　　要：在2型糖尿病并发症中,心血管病变是最主要的致死原因。胰高血糖素样肽-1(GLP-1)作为一种新型的糖尿病治疗药物,不仅可在促进胰岛素分泌的同时,抑制胰高血糖素分泌,还能有效改善2型糖尿病心血管并发症。现就GLP-1受体激动剂治疗2型糖尿病心血管并发症的研究进展做一综述。Among the complications of type 2 diabetes mellitus,cardiovascular disease is the main cause of death.Glucagon-like peptide-1(GLP-1),as a noveltreatment drugfordiabetes,can not only promote insulin secretion,but also inhibit glucagon secretion,and effectively improve cardiovascular complicationsoftype 2 diabetes mellitus.This article reviews the progress of GLP-1 receptor agonists in the treatment of cardiovascular complications oftype 2 diabetes mellitus.

关 键 词：胰高血糖素样肽-1 2型糖尿病 心血管并发症 

分 类 号：R587.2[医药卫生—内分泌]